The purpose of this study is to assess the long term treatment outcomes of Growth Hormone treatment in patients who are prescribed and treated with Genotropin. Also, plan to determine the relationships between clinical status, dosage schedule and response to Genotropin treatment. This study will also contribute to our knowledge of adult Growth Hormone Deficiency, including transition period in Childhood Onset Growth Hormone Deficiency and its treatment.
Patients within inclusion criteria are asked to participate in the study.
Study Type
OBSERVATIONAL
Enrollment
377
Non Interventional Study
Vastra Gotalands Regionen
Skövde, Skaraborg, Sweden
Landstinget Dalarna
Falun, Sweden
Sahlgrenska University hospital
Gothenburg, Sweden
Central Hospital/ Department of Medicine
Kristianstad, Sweden
Universitetssjukhuset, EM-kliniken
Linköping, Sweden
Ljungby Lasarettet
Ljungby, Sweden
University Hospital SUS
Malmo, Sweden
Landstinget i Stockholms Lan
Stockholm, Sweden
Karolinska Universitetssjukhuset, Kliniken for Endokrinologi
Stockholm, Sweden
Akademiska sjukhuset / Medicincentrum, Diabetes- och Endokrinsektionen
Uppsala, Sweden
...and 2 more locations
Number of Participants Classified According to Insulin-like Growth Factor (IGF-I) Assessments
IGF-I along with growth hormone helps promote normal bone and tissue growth and development. Categories for assessment for participant's post-baseline IGF-I values: (1) IGF-I LLN = if any of assessments of IGF-I post-baseline visit was lower than lower limit of normal (LLN); (2) IGF-I ULN = If any of assessments of IGF-I post-baseline visit was greater than upper level of normal (ULN); (3) IGF-I unknown = no IGF-I reported; (4) Within reference range = IGF-I levels within normal range. Following is normal reference range of IGF-I in nanogram per milliliter. 18 Years of age (Y): Male =162-541, Female =170-640; 19 Y: Male =138-442, Female =147-527; 20 Y: Male =122-384,Female =132-457; 21-25 Y=116-341; 26-30 Y=117-321; 31-35 Y=113-297; 36-40 Y=106-277; 41-45 Y =98-261; 46-50 Y=91-246; 51-55 Y=84-233; 56-60 Y=78-220; 61-65 Y=72-207; 66-70 Y=67-195; 71-75 Y=62-184; 76-80 Y=57-172; \>80 Y=53-162. There was no differentiation for male and female in normal range of IGF-I after 20 years of age.
Time frame: Up to 5 years (after baseline visit)
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received Genotropin without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.
Time frame: Baseline up to 5 years
Number of Treatment Related Adverse Events
Treatment-related AEs refer to AEs that have a causal relationship with the treatment or usage. If there was any relationship between AE and Genotropin treatment,that was judged by investigator.
Time frame: Baseline up to 5 years
Number of Adverse Events Leading to Withdrawal of Genotropin Treatment
An AE is any untoward medical occurrence in a participant administered a medicinal product that need not necessarily have a causal relationship with the product treatment or usage. An SAE is any untoward medical occurrence in a participant administered a medicinal or nutritional product at any dose that resulted to death, life-threatening, hospitalization or prolongation of hospitalization, persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); and congenital anomaly/birth defect.
Time frame: Baseline up to 5 years
Number of Participants Who Discontinued Study Due to Adverse Events
An AE is any untoward medical occurrence in a participant administered a medicinal product that need not necessarily have a causal relationship with the product treatment or usage. An SAE is any untoward medical occurrence in a participant administered a medicinal or nutritional product at any dose that resulted to death, life-threatening, hospitalization or prolongation of hospitalization, persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); and congenital anomaly/birth defect. Participants who discontinued study due to AEs were reported.
Time frame: Baseline up to 5 years
Weight of Participants at Baseline, Years 1, 2, 3, 4 and 5
Weight of participants was measured in kilograms (kg).
Time frame: Baseline, Year 1, 2, 3, 4, 5
Change From Baseline in Weight of Participants at Years 1, 2, 3, 4 and 5
Weight of participants was measured in kg.
Time frame: Baseline, Year 1, 2, 3, 4, 5
Height of Participants at Baseline, Years 1, 2, 3, 4 and 5
Height of participants was measured in centimeters.
Time frame: Baseline, Year 1, 2, 3, 4, 5
Change From Baseline in Height of Participants at Years 1, 2, 3, 4 and 5
Height of participants was measured in centimeters.
Time frame: Baseline, Year 1, 2, 3, 4, 5
Body Mass Index (BMI) of Participants at Baseline, Years 1, 2, 3, 4 and 5
BMI was defined as an index for assessing overweight and underweight and was obtained by dividing body weight in kilograms (kg) by height in meters squared (m\^2).
Time frame: Baseline, Year 1, 2, 3, 4, 5
Change From Baseline in Body Mass Index of Participants at Years 1, 2, 3, 4 and 5
BMI was defined as an index for assessing overweight and underweight and was obtained by dividing body weight in kilograms (kg) by height in m\^2.
Time frame: Baseline, Year 1, 2, 3, 4, 5
Blood Pressure (BP) of Participants at Baseline, Years 1, 2, 3, 4 and 5
Measurement of BP included supine systolic blood pressure (SBP) and diastolic blood pressure (DBP).
Time frame: Baseline, Year 1, 2, 3, 4, 5
Change From Baseline in Blood Pressure of Participants at Years 1, 2, 3, 4 and 5
Measurement of BP included supine SBP and DBP.
Time frame: Baseline, Year 1, 2, 3, 4, 5
Heart Rate of Participants at Baseline, Years 1, 2, 3, 4 and 5
Heart rate was measured in supine position.
Time frame: Baseline, Year 1, 2, 3, 4, 5
Change From Baseline in Heart Rate of Participants at Years 1, 2, 3, 4 and 5
Heart rate was measured in supine position.
Time frame: Baseline, Year 1, 2, 3, 4, 5
Percentage of Participants With Body Composition Assessments at Baseline, Years 1, 2, 3 and 4
Body composition included parameters fat mass and muscle mass.
Time frame: Baseline, Year 1, 2, 3, 4
Percentage of Participants With Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Investigation at Baseline, Years 1, 2, 3, 4 and 5
CT is a diagnostic imaging test used to create detailed images of internal organs, bones, soft tissue and blood vessels. MRI investigation uses strong magnetic field and radio waves to create detailed images of the organs and tissues within the body.
Time frame: Baseline, Year 1, 2, 3, 4, 5
Percentage of Participants With Any Change From Baseline in Hormone Abnormalities at Years 1, 2, 3, and 4
Hormones that were evaluated were thyroid stimulating hormone, adrenocorticotropic hormone, luteinizing hormone, follicle-stimulating hormone, antidiuretic hormone and prolactin hormone. Abnormalities were judged by the investigator.
Time frame: Baseline, Year 1, 2, 3, 4
Percentage of Participants With Any Concomitant Medication at Baseline and During Follow-up
Percentage of participants taking any medications other than Genotropin (concomitant medication) are reported.
Time frame: Baseline, Follow-up (during 28 days after last dose of Genotropin treatment)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.